SCHEMBL21224261

SCHEMBL21224261

CN(C)S(=O)(=O)c1cccc(C(=O)NCC(=O)Nc2nc(-c3ccc4c(c3)OCCO4)cs2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 11/20 0.58
▸ SMN1; SMN2 Q16637 11/20 0.58
▸ MAPT P10636 11/20 0.58
▸ NPC1 O15118 10/20 0.58
▸ LMNA P02545 8/20 0.58
▸ ALDH1A1 P00352 7/20 0.58
▸ NFKB1 P19838 2/20 0.58
▸ NFKB2 Q00653 2/20 0.58
▸ RELA Q04206 2/20 0.58
▸ KMT2A Q03164 11/20 0.56
▸ MEN1 O00255 10/20 0.56
▸ GAA P10253 1/20 0.56
▸ CLK1 P49759 2/20 0.56
▸ KDM4E B2RXH2 7/20 0.54
▸ POLB P06746 2/20 0.51
▸ TSHR P16473 2/20 0.51
▸ HSD17B10 Q99714 2/20 0.51
▸ HTT P42858 2/20 0.50
▸ KDM1A O60341 1/20 0.49
▸ MAOA P21397 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21241871 0.91 RAB9A (0.61) RAB9ASMN1; SMN2MAPTNPC1LMNA
SCHEMBL21224171 0.86 MAPT (0.54) RAB9ASMN1; SMN2MAPTNPC1LMNA
SCHEMBL21241816 0.86 LMNA (0.56) RAB9ASMN1; SMN2MAPTNPC1LMNA
SCHEMBL21225220 0.86 MAPT (0.52) RAB9ASMN1; SMN2MAPTNPC1LMNA
SCHEMBL21225311 0.86 MAPT (0.58) RAB9ASMN1; SMN2MAPTNPC1LMNA
SCHEMBL25184182 0.85 MAPT (0.53) RAB9ASMN1; SMN2MAPTNPC1LMNA
SCHEMBL22971650 0.85 MAPT (0.51) RAB9ASMN1; SMN2MAPTNPC1LMNA
SCHEMBL21224293 0.85 MAPT (0.55) RAB9ASMN1; SMN2MAPTNPC1LMNA
SCHEMBL21225178 0.85 ALDH1A1 (0.51) RAB9ASMN1; SMN2MAPTNPC1LMNA
SCHEMBL23704982 0.84 MEN1 (0.51) RAB9ASMN1; SMN2MAPTLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230138480-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-04 — — US disclosed
US-20230138480-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-04 — — US disclosed
US-20210038611-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2021-02-11 — — US disclosed
EP-3746124-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2020-12-09 — — EP disclosed
WO-2019152437-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2019-08-08 — — WO disclosed
WO-2019152437-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2019-08-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230138480-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB RAB9A 572/4885SMN1; SMN2 40/4885MAPT 2074/4885
US-20210038611-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB RAB9A 572/4885SMN1; SMN2 40/4885MAPT 2074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback